Abstract
The availability of active monoclonal antibodies has altered the treatment paradigms for patients with non-Hodgkins lymphomas (NHL). Nevertheless, some patients do not respond, while almost all of the others eventually relapse and require additional treatment. Thus, more effective alternatives are needed. Radioimmunotherapy (RIT) is an attractive option because of the inherent radiosensitivity of most NHL. Yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab are the first two radioimmunoconjugates currently available for clinical use. These agents appear comparably active in patients with follicular and low-grade NHL after failure following chemotherapy and/or rituximab. Activity has also been demonstrated against other histologies, including diffuse large B-cell NHL, mantle cell NHL, and transformed NHL. Toxicities primarily include myelosuppression, with a potential risk of treatmentassociated myelodysplastic syndrome and acute myelogenous leukemia. Current clinical trials are attempting to optimize the use of these agents by evaluating them earlier in the course of the disease, and sequenced with a variety of chemotherapy regimens. Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL.
Keywords: radioisotope, ibritumomab, tositumomab, acute myelogenous leukemia (AML), Southwest Oncology Group (SWOG)
Current Drug Targets
Title: Radioimmunotherapy of Non-Hodgkins Lymphomas
Volume: 7 Issue: 10
Author(s): Bruce D. Cheson
Affiliation:
Keywords: radioisotope, ibritumomab, tositumomab, acute myelogenous leukemia (AML), Southwest Oncology Group (SWOG)
Abstract: The availability of active monoclonal antibodies has altered the treatment paradigms for patients with non-Hodgkins lymphomas (NHL). Nevertheless, some patients do not respond, while almost all of the others eventually relapse and require additional treatment. Thus, more effective alternatives are needed. Radioimmunotherapy (RIT) is an attractive option because of the inherent radiosensitivity of most NHL. Yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab are the first two radioimmunoconjugates currently available for clinical use. These agents appear comparably active in patients with follicular and low-grade NHL after failure following chemotherapy and/or rituximab. Activity has also been demonstrated against other histologies, including diffuse large B-cell NHL, mantle cell NHL, and transformed NHL. Toxicities primarily include myelosuppression, with a potential risk of treatmentassociated myelodysplastic syndrome and acute myelogenous leukemia. Current clinical trials are attempting to optimize the use of these agents by evaluating them earlier in the course of the disease, and sequenced with a variety of chemotherapy regimens. Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL.
Export Options
About this article
Cite this article as:
Cheson D. Bruce, Radioimmunotherapy of Non-Hodgkins Lymphomas, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559157
DOI https://dx.doi.org/10.2174/138945006778559157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Current Cancer Drug Targets Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets Electroporation in DNA Vaccination Protocols Against Cancer
Current Drug Metabolism Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Therapeutic Uses of HSP90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
Current Drug Metabolism HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging Kits for Hexosamine Biosynthetic Pathway in Oncology
Current Medicinal Chemistry Gene Delivery for Cancer Therapy
Current Drug Delivery Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Current Stem Cell Research & Therapy Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery